CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 17 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −5,253 | 141,785 | ||
| 2022-02-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise | +5,251 | $2.06 | $11K | 7,709 |
| 2022-02-10 | Horn Kinney CHIEF BUSINESS OFFICER | Returned to the company | −5,251 | 2,458 | ||
| 2022-02-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −5,251 | 147,038 | ||
| 2022-02-01 | Myles David C. CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (Right to Buy) | +118,750 | 118,750 | ||
| 2022-02-01 | Kushner Peter J. CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +61,750 | 61,750 | ||
| 2022-02-01 | Harmon Cyrus CHIEF TECHNOLOGY OFFICER | Grant or award · Stock Option (Right to Buy) | +104,500 | 104,500 | ||
| 2022-02-01 | Horn Kinney CHIEF BUSINESS OFFICER | Grant or award · Stock Option (Right to Buy) | +133,000 | 133,000 | ||
| 2022-02-01 | Moriarty John B EVP, CH. LEGAL OFFICER & SEC. | Grant or award · Stock Option (Right to Buy) | +166,250 | 166,250 | ||
| 2022-02-01 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Grant or award · Stock Option (Right to Buy) | +247,000 | 247,000 | ||
| 2022-02-01 | Bohen Sean PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +812,250 | 812,250 | ||
| 2022-02-01 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2022-01-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise | +5,251 | $2.06 | $11K | 7,709 |
| 2022-01-10 | Horn Kinney CHIEF BUSINESS OFFICER | Sale | −5,251 | $6.85 | $36K | 2,458 |
| 2022-01-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −5,251 | 152,289 | ||
| 2021-12-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise | +5,251 | $2.06 | $11K | 7,709 |
| 2021-12-10 | Horn Kinney CHIEF BUSINESS OFFICER | Sale | −5,251 | $10.39 | $55K | 2,458 |
| 2021-12-10 | Horn Kinney CHIEF BUSINESS OFFICER | Option exercise · Stock Option (Right to Buy) | −5,251 | 157,540 | ||
| 2021-12-10 | Myles David C. CHIEF DEVELOPMENT OFFICER | Sale | −10,000 | $10.30 | $103K | 582,901 |
| 2021-11-30 | BVF PARTNERS L P/IL Director | Purchase | +362,430 | $9.39 | $3.4M | 3,755,093 |
Page 15 of 21 · 402 trades